



JRW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventive Application of:

Gallagher et al.

Application No.: 10/722,357

Filed: November 24, 2003

For: ***Target for Therapy of Cognitive Impairment***

Examiner: Jezia Riley

Art Unit: 1637

Attorney Document No.: JHV-028.01  
(19546-2801)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: August 8, 2005.

*Angela Thumann*  
Angela Thumann

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR 1.97 (b)(3)**

Sir:

In compliance with the requirements of 37 C.F.R. 1.56 and 1.97(b)(3), submitted herewith on Form PTO-1449 is a list of publications known to the Applicants and their Attorney/Agent. A copy of each publication is also being submitted herewith. Applicants respectfully request that the Examiner consider the listed publications and indicate they were considered by making appropriate notations on the attached Form PTO-1449.

Applicants have listed dates of publication on the attached PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information in the cited documents was actually published or otherwise publicly available on the date indicated.


This submission does not represent that other searches have been made or that no better art exists. Nor does it constitute an admission that the cited documents are material or constitute

“prior art.” If the Examiner applies the listed documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute “prior art” under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.

Under 37 C.F.R. § 1.97 (b)(3), this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with this submission. However, the Commissioner is authorized to charge any deficiencies or credit any overpayment to/from our **Deposit Order Account, No. 06-1448; Reference JHV-028.01**


Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1000.

Respectfully Submitted,

  
\_\_\_\_\_  
**Gillian M. Fenton**  
Reg. No. 36,508  
Attorney /or Agent for Applicants

Date: August 8, 2005

**Customer No.: 25181**  
Patent Group  
Foley Hoag LLP  
155 Seaport Boulevard  
Boston, MA 02210

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION</b> IN AN APPLICATION (Use several sheets if necessary)		Docket Number (Optional) <b>JHV-028.01</b>		Application Number <b>10/722,357</b>		
		Applicant <b>Gallagher et al.</b>		Group Art Unit <b>1637</b>		
		Filing Date <b>November 24, 2003</b>				
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
<b>FOREIGN PATENT DOCUMENTS</b>						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES      NO
	AL					
	AM					
	AN					
	AO					
	AP					
<b>OTHER DOCUMENTS</b> <span style="float: right;">(Including Author, Title, Date, Pertinent Pages Etc.)</span>						
	AQ	H.K. Manji et al., "Neuroplasticity and cellular resilience in mood disorders", Molecular Psychiatry, 2000, 5, pages 578-593.				
	AR	Pierre N. Tariot M.D. et al., "Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales", Advanced Drug Delivery Reviews, 54, 2002, pages 1567-1577.				
	AS					
EXAMINER					DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						